Novartis Gains 1.88% on Acquisition of Avidity Biosciences and Positive CHMP Opinion

Stock Performance Overview

On February 27, 2026, Novartis AG (ticker symbol: NVS) exhibited a notable performance in the U.S. stock market. The stock opened at $169.11 and closed at $168.62, reflecting a gain of $3.11 or approximately 1.88% from the previous close of $165.51. During the trading session, the stock reached a high of $170.46 and a low of $168.56, indicating a relatively stable intraday price movement. The trading volume for the day was approximately 3.19 million shares, which contributed to a total market capitalization of around $321.75 billion.

Daily Price Movements

• Opening Price: $169.11
• Closing Price: $168.62
• Highest Price: $170.46
• Lowest Price: $168.56
• Volume: 3.19 million shares
• Percentage Change: +1.88%

The stock's performance today can be attributed to several factors, including recent corporate developments, product advancements, and market sentiment surrounding the pharmaceutical sector.

Key News and Developments

1. Acquisition of Avidity Biosciences: One of the major announcements affecting Novartis's stock today was the completion of its acquisition of Avidity Biosciences. This strategic move is expected to strengthen Novartis's late-stage neuroscience pipeline and advance its xRNA strategy. The acquisition is seen as a potential catalyst for future growth and innovation within the company, unlocking multi-billion-dollar opportunities with planned product launches before 2030. This news was released on February 27, 2026, and likely contributed to the positive market reaction.
   Read more about the acquisition
2. Positive CHMP Opinion for Remibrutinib: Novartis also announced that it received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its drug Remibrutinib for chronic spontaneous urticaria. This favorable regulatory update may enhance investor confidence in Novartis's product pipeline and future revenue prospects.
   Read more about the CHMP opinion
3. Expansion of Manufacturing Capabilities: The company is also expanding its manufacturing capabilities by building a new radioligand therapy site in Denton, Texas. This facility is part of a broader strategy to enhance production and deliver next-generation treatments to patients. Such expansions are crucial for maintaining competitive advantage in the pharmaceutical industry.
   Read more about the new manufacturing site
4. Market Sentiment and Analyst Ratings: Market analysts currently hold a consensus rating of "Hold" on Novartis, with expectations for moderate growth in earnings. The average target price set by analysts is approximately $150.00, indicating potential upside from the current trading levels. This sentiment reflects cautious optimism amidst ongoing challenges in the pharmaceutical sector, including patent expirations and competition from generics.
   Read more about analyst ratings

Conclusion

In summary, Novartis AG's stock performance on February 27, 2026, was marked by a positive closing price, driven by strategic acquisitions, favorable regulatory updates, and expansion plans. The overall market sentiment appears cautiously optimistic, reflecting the company's potential for growth despite the challenges inherent in the pharmaceutical industry. Investors and analysts will likely continue to monitor Novartis's developments closely as the company navigates its future in a competitive landscape.